Global Small Caps Nutra Pharma Corporation (OTCQB: NPHC) to Hit 10c

Global Small Caps Nutra Pharma Corporation (OTCQB: NPHC) to Hit 10c

Global Small Caps Nutra Pharma Corporation (OTCQB: NPHC) to Hit 10c

Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company’s stock with a price target of $0.10


The report is available at:


“We certainly appreciate any coverage of our company, especially as it pertains to the work that we are doing and the potential value of our stock,” commented Rik J Deitsch, CEO of Nutra Pharma. “We have been getting a lot of press lately. In fact, we were recently featured on NBC News Miami in a piece that has since been picked up nationally,” he continued. “The current report on Global Small Caps focusses on our OTC pain drugs, Nyloxin and Pet Pain-Away. These are clinically proven, all-natural products that are available today to deal with pain and inflammation in people and their pets. The report also outlines the future of the Company’s drug platform, especially the opportunity with our Multiple Sclerosis drug, RPI-78M,” he concluded.


According to their website, Global Small Caps, LLC is an independent company that researches public small caps in order to bring the latest investment trends to the average investor.


About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit: or

The following two tabs change content below.
Shayne Heffernan Funds Manager at HEFFX holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services.

Latest posts by Shayne Heffernan (see all)

You must be logged in to post comments :